Sai Parenterals Limited, a pharmaceutical formulations company with a growing presence in branded generics and CDMO services, is launching its mainboard IPO on March 24, 2026. This IPO is particularly relevant for investors looking to evaluate opportunities in India’s pharmaceutical manufacturing and export ecosystem, especially those tracking mid-sized pharma companies with scalable operations.
This detailed Sai Parenterals IPO review is designed for retail investors, HNIs, and market participants who want a clear understanding of IPO fundamentals, valuation, GMP trends, financials, and risks before making an investment decision.
Table Of Contents
- Sai Parenterals IPO Overview
- Sai Parenterals IPO Timeline
- Sai Parenterals IPO Details
- Company Overview Of Sai Parenterals
- Sai Parenterals Financial Performance
- Use Of IPO Proceeds
- Sai Parenterals IPO Valuation And Peer Comparison
- Sai Parenterals IPO GMP And Market Sentiment
- Key Strengths Of Sai Parenterals
- Risks To Consider Before Investing
- Who Should Invest In Sai Parenterals IPO
- Conclusion
- FAQs On Sai Parenterals IPO
Sai Parenterals IPO is a mainboard public issue aiming to raise approximately ₹408.79 crore. The IPO includes a mix of a fresh issue and an offer for sale, making it relevant to both company expansion and a partial promoter exit.
For investors evaluating IPOs in the pharma sector, this offering stands out for its focus on injectable manufacturing, CDMO services, and export-led growth, particularly in regulated markets such as Australia.
The IPO schedule is critical for investors planning their application strategy. Below is the complete timeline:
|
Event
|
Date
|
|
IPO Opens
|
March 24, 2026
|
|
IPO Closes
|
March 27, 2026
|
|
Allotment Date
|
March 30, 2026
|
|
Refund Initiation
|
April 1, 2026
|
|
Shares Credited
|
April 1, 2026
|
|
Listing Date
|
April 2, 2026
|
|
Anchor Investors
|
March 23, 2026
|
/content-assets/13841edec76849859e82b3b297016cef.png)
This timeline helps investors track allotment status, listing expectations, and liquidity planning.
Sai Parenterals IPO pricing and lot size are structured to attract both retail and institutional investors.
|
Category
|
Details
|
|
Issue Size
|
₹408.79 crore
|
|
Fresh Issue
|
₹285 crore
|
|
Offer For Sale
|
₹123.79 crore
|
|
Price Band
|
₹372 to ₹392
|
|
Face Value
|
₹5
|
|
Lot Size
|
38 shares
|
|
Minimum Investment
|
₹14,896
|
|
Listing Exchange
|
BSE and NSE
|
Investor Allocation
|
Category
|
Allocation
|
|
Retail Investors
|
35%
|
|
QIB
|
Up to 50%
|
|
NII
|
15%
|
Lot Size Breakdown
|
Category
|
Shares
|
Investment Amount (₹392)
|
|
Retail
|
38
|
14,896
|
|
sNII
|
532
|
208,544
|
|
bNII
|
2,584
|
1,012,928
|
This structure ensures participation across investor categories while maintaining accessibility for retail investors.
Sai Parenterals Limited, incorporated in 2001, operates in pharmaceutical formulations manufacturing with a focus on branded generics and contract development and manufacturing organisation services.
The company serves both domestic and international markets, with exports playing a significant role in revenue generation.
Business Segments
- Branded generics across therapeutic areas
- CDMO services for pharmaceutical companies
- Export-focused formulations manufacturing
Product Portfolio
The company manufactures a wide range of dosage forms:
- Injectables
- Tablets
- Capsules
- Ointments
Therapeutic coverage includes:
- Cardiovascular
- Anti-diabetic
- Antibiotics
- Anti-inflammatory
Manufacturing And Certifications
Sai Parenterals operates five manufacturing facilities:
- Four units in Hyderabad
- One unit in Ongole
Key regulatory accreditations include:
- WHO-GMP
- TGA Australia
- PIC/S
These certifications allow the company to export to regulated markets, enhancing credibility and pricing power.
Export Presence
- Exports to 10 countries
- Australia contributes around 63% of FY25 export revenue
This concentration provides scale but also introduces geographic risk.
Sai Parenterals has demonstrated consistent revenue growth and improved profitability, making it relevant to investors seeking scalable pharma companies.
|
Year
|
Revenue (₹ Cr)
|
PAT (₹ Cr)
|
|
FY23
|
97.03
|
4.38
|
|
FY24
|
155.18
|
8.42
|
|
FY25
|
163.74
|
14.45
|
Key Financial Metrics
|
Metric
|
Value
|
|
EBITDA Margin
|
24.18%
|
|
ROE
|
15.09%
|
|
ROCE
|
28.92%
|
|
Debt
|
₹93.95 crore
|
|
NAV
|
₹35.98
|
Financial Insights
- Revenue growth from FY23 to FY25 indicates strong demand expansion
- PAT growth of 71% YoY in FY25 reflects margin improvement
- EBITDA margins above 24% indicate operational efficiency
- Debt levels remain moderate, requiring monitoring post IPO
The utilisation of IPO funds is a key factor in evaluating long-term growth potential.
|
Purpose
|
Allocation
|
|
Capacity Expansion
|
₹110.8 crore
|
|
R&D Centre
|
₹18 crore
|
|
Debt Repayment
|
₹14.3 to ₹20 crore
|
|
Working Capital
|
₹33 crore
|
|
Acquisition Funding
|
₹35.6 to ₹36 crore
|
|
General Corporate
|
₹73 crore
|
Strategic Implications
- Capacity expansion supports volume growth
- R&D investment strengthens product pipeline
- Debt repayment improves the balance sheet
- Acquisition funding enhances international presence
At the upper price band of ₹392, Sai Parenterals IPO is valued at approximately 72x FY25 earnings, which is relatively high compared to peers.
Peer Comparison
|
Company
|
Key Insight
|
|
Sai Life Sciences
|
Higher scale, lower relative valuation
|
|
Innova Captab
|
Significantly lower P/E multiple
|
|
Senores Pharmaceuticals
|
Moderate valuation range
|
/content-assets/c0c436f969ec40c2a53c43d721e874d6.png)
Valuation Analysis
- High P/E suggests growth expectations are already priced in
- Lower revenue scale compared to peers
- Margins are competitive, but return ratios are moderate
Investors should carefully assess whether future growth justifies the premium valuation.
Investors often use Grey Market Premium to gauge listing expectations.
- Current GMP range is approximately ₹25 to ₹30
- Implies potential listing gain of 6% to 8%
What GMP Indicates
- Moderate demand in the unofficial market
- Not excessively overheated, indicating balanced sentiment
- Reflects cautious optimism among investors
However, GMP is not an official indicator and should not be the sole basis for investment decisions.
Before applying, review live GMP trends, financials, and subscription data of Sai Parenterals IPO to make an informed decision on Finology Ticker.
Sai Parenterals has several operational and strategic advantages:
- Diversified product portfolio across therapies and dosage forms
- Strong expertise in injectables manufacturing
- Regulatory-approved facilities enabling exports
- Growing CDMO business segment
- In-house R&D team with 34 professionals
- Acquisition-driven expansion strategy
These strengths position the company well in the competitive pharma manufacturing space.
Investors should evaluate the following risks carefully:
- Heavy reliance on the injectables segment
- Geographic concentration in Hyderabad manufacturing units
- Regulatory risks related to inspections and compliance
- Dependence on key suppliers for raw materials
- Customer concentration risk
- Execution risk in expansion and acquisitions
- Forex risk due to export exposure
Understanding these risks is critical before subscribing to the IPO.
This IPO may be suitable for:
- Investors looking for exposure to the pharmaceutical manufacturing sector
- Long-term investors interested in CDMO growth stories
- Investors are comfortable with high valuation IPOs
- Portfolio diversification into mid-cap pharma companies
Investment Strategy
- Consider allocating 5% to 10% of the portfolio
- Track subscription levels and institutional participation
- Evaluate post-listing performance before adding more
Sai Parenterals IPO presents a mix of strong growth potential and valuation concerns. The company benefits from a diversified product portfolio, export presence, and a growing CDMO business, all of which align with long-term trends in the pharmaceutical sector.
However, the relatively high valuation, moderate return ratios, and operational risks require careful consideration. Investors with a long-term perspective and moderate risk appetite may consider subscribing selectively, while others may prefer to wait for post-listing price discovery.
Looking beyond the Sai Parenterals IPO, check all current IPO, GMP trends, and subscription data in one place on Finology Ticker.
- What is the Sai Parenterals IPO date?
Sai Parenterals IPO opens on March 24, 2026, and closes on March 27, 2026.
- What is the price band of Sai Parenterals IPO?
The price band is set between ₹372 and ₹392 per share.
- What is the minimum investment for retail investors?
Retail investors need to invest a minimum of ₹14,896 for one lot of 38 shares.
- Is Sai Parenterals IPO good for long-term investment?
It can be considered for long-term investment due to growth in CDMO and exports, but valuation and risks should be evaluated.
- What is Sai Parenterals IPO GMP today?
The GMP is around ₹25-₹30, indicating moderate listing expectations.
- Where will Sai Parenterals IPO be listed?
The shares will be listed on BSE and NSE.